AP Pharma's drug for chemotherapy-induced nausea denied approval
March 28 (Reuters) - U.S. health regulators denied approval to A.P. Pharma Inc's drug for treating chemotherapy-induced nausea and vomiting, and asked for additional analysis of existing late-stage data on the drug.
The U.S. Food and Drug Administration also asked for a study that can test the usability of the drug's syringe system.
The agency had earlier rejected the approval of the drug, APF530, in March 2010, citing concerns about its two-syringe administration system and deficiencies in the company's contract manufacturing facilities.
A.P. Pharma resubmitted its application in September last year after switching to a single-syringe system and conducting additional metabolism studies as required by the FDA.
- Islamic State threat 'beyond anything we've seen': Pentagon
- Oklahoma City policeman arrested for raping women while on patrol
- U.S. says Russia must pull convoy from Ukraine or face more sanctions |
- Gaza gunmen execute 'collaborators'; mortar kills Israeli boy |
- Exclusive: Apple iPhone 6 screen snag leaves supply chain scrambling |